GlassScriptPhysician profile
Danny Jandali
NPI 1063827590
$1,302.44
in general payments reported to CMS, 2019-2025
11 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.01 · 2021: $131 · 2022: $82.67 · 2023: $590 · 2024: $311 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.24 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.27 | 2023-2025 | |
| Stryker Corporation | $253.50 | 2019-2023 | N/A |
| Aerin Medical INC. | $133.35 | 2023 | |
| Galderma Laboratories, L.P. | $123.01 | 2022-2024 | |
| Glaxosmithkline, LLC. | $105.79 | 2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $105.69 | 2023-2025 | Dupixent |
| Optinose US, INC. | $86.07 | 2021-2022 | |
| Kerecis Limited | $46.87 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Acclarent, INC | $33.31 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $22.38 | 2024 | |
| Csl Behring | $17.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Jandali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.